Tumour Initiation: Danger zone
When a cell multiplies, differentiates or dies, it relies on a number of complex signalling networks. In turn, mutations in nodes that increase or decrease communication through these networks frequently result in diseases. An example is the Ras gene family, which is often mutated in cancer: activating mutations at certain Ras codons leads to cells proliferating and forming tumours (Prior et al., 2020). However, too much activation can trigger safety mechanisms and cause the cell to die. How much Ras activity is enough to drive cancer is therefore a fundamental question.
For a long time it was assumed that any mutation that activated Ras proteins would lead to disease. New evidence, however, has revealed that local cellular and disease context creates important differences between Ras mutants (Killoran and Smith, 2019; Haigis et al., 2019). In one study in mice, for example, out of twelve different mutations introduced in equal quantities in a Ras gene called KRAS, only five led to the animals developing lung tumours (Winters et al., 2017). Intriguingly, which mutation drives disease was different depending on the type of cancer, and the genetic background of the mouse strain. These data imply mutation-specific differences in Ras biology.
Now, in eLife, Siqi Li and Christopher Counter from Duke University report having described the optimal conditions in which various Ras mutations operate (Li et al., 2018). According to a previously proposed ‘sweet spot’ model, there is a level of Ras activity high enough to promote tumour formation, but not to lead to cell death (Li and Counter, 2021). To examine this further, a classic mouse cancer model was exposed to urethane, a chemical found in fermented foods that consistently generates a codon Q61* mutation in KRAS and leads to Ras-driven lung cancer (Westcott et al., 2015; Dwyer-Nield et al., 2010). Codon Q61* mutations are known to lead to more Ras activity than codon G12* mutations (Burd et al., 2014; Figure 1); this suggests that codon Q61* mutations, rather than G12*, have optimal levels of Ras signalling in this urethane-induced cancer model.
To test if weaker G12* mutations could also induce cancer in this model, a mouse strain with increased KRAS expression (called KRASex3op) was exposed to urethane, artificially boosting the amount of active Ras. Even though Q61* mutations were still generated, G12* mutations were found to drive the development of tumours in these animals; this demonstrated that the switch was due to Ras biological properties, a result consistent with the sweet spot model.
Whether strong Ras signalling – which would normally induce cell death – could be moved into the optimal activity zone was explored by deleting p53 in wild type mice. This gene instructs cells to die when oncogenic stress induces unrepairable DNA damage. As predicted, p53-/-, KRASex3opmouse strains with increased KRAS expression and depleted p53 could tolerate high levels of Q61* mutations (Figure 1). Intriguingly, p53-/- mice also showed an endogenous amplification of KRAS, which moved G12* mutations up into the optimal Ras signalling zone. This was not due to additional copies of Ras genes, but to an increase in the production of messenger RNAs carrying the G12* change.
Together, these data reveal a narrow window of cancer-causing Ras activity; this suggests that the role of specific Ras mutations, and how they are combined, needs to be considered for research design and treatment options. However, further studies ought to formally quantify how a range of Ras mutations and combinations differ in their relative activity. This will help to confirm whether the model holds true across a broader range of cancer contexts, and to more precisely determine optimal Ras activity.
The model is based on observed endpoints, after tumours have grown. Yet, it is reasonable to assume that the optimal level of Ras signalling changes as the cancer develops: for instance, Ras alleles are amplified and lost over the life history of cancer, and in response to therapy (Burgess et al., 2017). An exciting observation was the increase in KRAS messenger RNA to help modulate Ras activity; however, this still needs to be validated by measuring Ras protein levels. Finally, how variable levels of Ras activity then variously impact wider cancer signalling networks is a big question that remains unanswered.
References
-
Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallelJournal of Biological Chemistry 294:9937–9948.https://doi.org/10.1074/jbc.RA119.008653
-
A model for RAS mutation patterns in cancers: finding the sweet spotNature Reviews Cancer 18:767–777.https://doi.org/10.1038/s41568-018-0076-6
-
The frequency of Ras mutations in cancerCancer Research 80:2969–2974.https://doi.org/10.1158/0008-5472.CAN-19-3682
Article and author information
Author details
Publication history
Copyright
© 2021, Butt and Prior
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 919
- views
-
- 68
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
In tumors with WT p53, alternate mechanisms of p53 inactivation are reported. Here, we have identified a long noncoding RNA, PITAR (p53 Inactivating TRIM28 Associated RNA), as an inhibitor of p53. PITAR is an oncogenic Cancer/testis lncRNA and is highly expressed in glioblastoma (GBM) and glioma stem-like cells (GSC). We establish that TRIM28 mRNA, which encodes a p53-specific E3 ubiquitin ligase, is a direct target of PITAR. PITAR interaction with TRIM28 RNA stabilized TRIM28 mRNA, which resulted in increased TRIM28 protein levels and reduced p53 steady-state levels due to enhanced p53 ubiquitination. DNA damage activated PITAR, in addition to p53, in a p53-independent manner, thus creating an incoherent feedforward loop to inhibit the DNA damage response by p53. While PITAR silencing inhibited the growth of WT p53 containing GSCs in vitro and reduced glioma tumor growth in vivo, its overexpression enhanced the tumor growth in a TRIM28-dependent manner and promoted resistance to Temozolomide. Thus, we establish an alternate way of p53 inactivation by PITAR, which maintains low p53 levels in normal cells and attenuates the DNA damage response by p53. Finally, we propose PITAR as a potential GBM therapeutic target.
-
- Cancer Biology
- Neuroscience
Cancer patients often experience changes in mental health, prompting an exploration into whether nerves infiltrating tumors contribute to these alterations by impacting brain functions. Using a mouse model for head and neck cancer and neuronal tracing, we show that tumor-infiltrating nerves connect to distinct brain areas. The activation of this neuronal circuitry altered behaviors (decreased nest-building, increased latency to eat a cookie, and reduced wheel running). Tumor-infiltrating nociceptor neurons exhibited heightened calcium activity and brain regions receiving these neural projections showed elevated Fos as well as increased calcium responses compared to non-tumor-bearing counterparts. The genetic elimination of nociceptor neurons decreased brain Fos expression and mitigated the behavioral alterations induced by the presence of the tumor. While analgesic treatment restored nesting and cookie test behaviors, it did not fully restore voluntary wheel running indicating that pain is not the exclusive driver of such behavioral shifts. Unraveling the interaction between the tumor, infiltrating nerves, and the brain is pivotal to developing targeted interventions to alleviate the mental health burdens associated with cancer.